Skip to main content

Fiscal Wizard · Single-issue tearsheet

ADMA / Jun 21, 2026 Run #7358

ADMA

ADMA Biologics, Inc.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Composite verdict

D 33.3 / 100
Bearish setup · Reversal 6 drivers · 4 gates blocking
  • Multi Top/Bottom
  • Fibonacci Retracement
  • Pin Bar
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 154th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 34Mean-reversion Bearish 30
  • Late-stage trendTrend signals have been live for 116 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -61%
Asset value $2.06Earnings power value $7.45Price $8.31

Priced above its no-growth earnings power value ($7.45/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

59.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 100
Margin of Safety 0
Return on Assets 90
OCF to Net Income 0
Return on Capital Employed 88
Cash Conversion 0

Technicals Bearish

6.7 / 100

Bearish setup leads (Multi Top/Bottom, Fibonacci Retracement, Pin Bar); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Fibonacci Retracement 18
Multi Top/Bottom 18
Pin Bar 24

Risk Gates

4 blocking 7 caution

4 guards active, 25 signals gated.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ADMA.